Vanguard Group
GALT icon

Vanguard Group’s Galectin Therapeutics GALT Stock Holding History

Vanguard Group’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$9.52M Buy
2,288,848
+40,881
+2% +$215K ﹤0.01% 2987
2025
Q3 		$9.52M Buy
2,247,967
+63,419
+3% +$239K ﹤0.01% 3005
2025
Q2 		$4.61M Sell
2,184,548
-7,954
-0.4% -$11.9K ﹤0.01% 3243
2025
Q1 		$2.67M Buy
2,192,502
+54,899
+3% +$77K ﹤0.01% 3390
2024
Q4 		$2.76M Buy
2,137,603
+3,398
+0.2% +$8.14K ﹤0.01% 3469
2024
Q3 		$5.87M Buy
2,134,205
+18,133
+0.9% +$44.5K ﹤0.01% 3207
2024
Q2 		$4.78M Buy
2,116,072
+136,181
+7% +$414K ﹤0.01% 3276
2024
Q1 		$4.73M Buy
1,979,891
+38,037
+2% +$72K ﹤0.01% 3320
2023
Q4 		$3.22M Hold
1,941,854
– – ﹤0.01% 3437
2023
Q3 		$3.73M Hold
1,941,854
– – ﹤0.01% 3368
2023
Q2 		$2.8M Hold
1,941,854
– – ﹤0.01% 3554
2023
Q1 		$4.08M Hold
1,941,854
– – ﹤0.01% 3399
2022
Q4 		$2.19M Buy
1,941,854
+1,047
+0.1% +$1.4K ﹤0.01% 3626
2022
Q3 		$3.16M Hold
1,940,807
– – ﹤0.01% 3558
2022
Q2 		$2.54M Hold
1,940,807
– – ﹤0.01% 3706
2022
Q1 		$3.13M Sell
1,940,807
-9,881
-0.5% -$19.1K ﹤0.01% 3761
2021
Q4 		$4.04M Sell
1,950,688
-2,731
-0.1% -$7.8K ﹤0.01% 3727
2021
Q3 		$7.58M Hold
1,953,419
– – ﹤0.01% 3406
2021
Q2 		$6.25M Buy
1,953,419
+21,110
+1% +$75.1K ﹤0.01% 3473
2021
Q1 		$4.19M Buy
1,932,309
+51,782
+3% +$116K ﹤0.01% 3620
2020
Q4 		$4.21M Buy
1,880,527
+31,099
+2% +$81.6K ﹤0.01% 3436
2020
Q3 		$4.94M Sell
1,849,428
-14,152
-0.8% -$39.6K ﹤0.01% 3151
2020
Q2 		$5.7M Buy
1,863,580
+28,080
+2% +$70.6K ﹤0.01% 3038
2020
Q1 		$3.6M Sell
1,835,500
-1,865
-0.1% -$4.54K ﹤0.01% 3114
2019
Q4 		$5.25M Buy
1,837,365
+22,903
+1% +$79.6K ﹤0.01% 3151
2019
Q3 		$6.66M Buy
1,814,462
+80,138
+5% +$290K ﹤0.01% 3029
2019
Q2 		$7.2M Buy
1,734,324
+125,092
+8% +$542K ﹤0.01% 3036
2019
Q1 		$8.22M Buy
1,609,232
+176,656
+12% +$848K ﹤0.01% 2926
2018
Q4 		$4.91M Hold
1,432,576
– – ﹤0.01% 3098
2018
Q3 		$8.61M Buy
1,432,576
+225,822
+19% +$1.24M ﹤0.01% 2991
2018
Q2 		$7.67M Buy
1,206,754
+40,441
+3% +$197K ﹤0.01% 3034
2018
Q1 		$5.53M Buy
1,166,313
+251,290
+27% +$1.17M ﹤0.01% 3101
2017
Q4 		$3.06M Buy
915,023
+64,075
+8% +$162K ﹤0.01% 3297
2017
Q3 		$1.8M Sell
850,948
-20,562
-2% -$40.7K ﹤0.01% 3435
2017
Q2 		$2.14M Buy
871,510
+134,165
+18% +$357K ﹤0.01% 3355
2017
Q1 		$1.7M Buy
737,345
+210,504
+40% +$317K ﹤0.01% 3428
2016
Q4 		$516K Sell
526,841
-62,682
-11% -$55.7K ﹤0.01% 3729
2016
Q3 		$667K Sell
589,523
-17,014
-3% -$30.2K ﹤0.01% 3683
2016
Q2 		$892K Buy
606,537
+2,490
+0.4% +$3.65K ﹤0.01% 3634
2016
Q1 		$864K Buy
604,047
+1,968
+0.3% +$2.64K ﹤0.01% 3638
2015
Q4 		$987K Buy
602,079
+6,700
+1% +$15.3K ﹤0.01% 3632
2015
Q3 		$1.39M Buy
595,379
+15,406
+3% +$36.3K ﹤0.01% 3529
2015
Q2 		$1.58M Sell
579,973
-29,490
-5% -$88.9K ﹤0.01% 3512
2015
Q1 		$2.04M Buy
609,463
+1,157
+0.2% +$4.13K ﹤0.01% 3406
2014
Q4 		$2.11M Buy
608,306
+11,683
+2% +$51.6K ﹤0.01% 3269
2014
Q3 		$3M Buy
596,623
+95,258
+19% +$742K ﹤0.01% 3101
2014
Q2 		$6.92M Buy
501,365
+59,596
+13% +$742K ﹤0.01% 2685
2014
Q1 		$6.76M Buy
441,769
+134,365
+44% +$1.91M ﹤0.01% 2673
2013
Q4 		$2.48M Buy
307,404
+146,813
+91% +$1.36M ﹤0.01% 3105
2013
Q3 		$1.6M Buy
160,591
+73,061
+83% +$493K ﹤0.01% 3220
2013
Q2 		$372K Buy
+87,530
New +$358K ﹤0.01% 3545

Other funds holding GALT

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group's GALT Position: Q4 2025 in Review

Vanguard Group increased its Galectin Therapeutics (GALT) stake by 1.8% in Q4 2025, buying an estimated $215K and bringing the position to 2,288,848 shares worth $9.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2987.

Vanguard Group first reported a position in GALT in Q2 2013 and has held it in 51 quarters since. 97 funds tracked by Wall St. Rank hold GALT as of Q4 2025.

  • Vanguard Group held 2,288,848 shares of Galectin Therapeutics worth $9.52M as of Q4 2025.
  • Vanguard Group bought 40,881 Galectin Therapeutics shares in Q4 2025, an estimated $215K.
  • Galectin Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2987 holding.
  • Vanguard Group first reported a position in Galectin Therapeutics in Q2 2013 and has held it in 51 quarters since.
  • 97 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.